Known targets — ChEMBL curated mechanism
AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA
The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387521 | 0.95 | TDP1 (0.55) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21195493 | 0.95 | TDP1 (0.55) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| Potassium Ion SCHEMBL2284212 | 0.95 | CYP1A2 (0.53) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| Potassium Ion SCHEMBL6284188 | 0.88 | GLS (0.52) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL34464125 | 0.83 | RAB9A (0.54) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL21997522 | 0.83 | RAB9A (0.54) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6790333 | 0.82 | TDP1 (0.71) | TDP1L3MBTL1CYP1A2CYP2D6CYP2C19 | |
| SCHEMBL2169798 | 0.81 | TDP1 (0.54) | TDP1L3MBTL1HDAC8HDAC3HDAC4 | |
| SCHEMBL30630031 | 0.81 | TDP1 (0.54) | TDP1L3MBTL1MAPTRAB9ASMN1; SMN2 | |
| SCHEMBL5839787 | 0.81 | TDP1 (0.54) | TDP1L3MBTL1CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678147-B1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | LEAD DISCOVERY CENTER GMBH (DE) | 2012-08-08 | — | — | EP | disclosed |
| US-8084457-B2 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | LEAD DISCOVERY CENTER GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| EP-1678147-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC Biotech AG (DE) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005026129-A1 | PHARMACEUTICALLY ACTIVE 4,6-DISUBSTITUTED AMINOPYRIMIDINE DERIVATIVES AS MODULATORS OF PROTEIN KINASES | GPC BIOTECH AG (DE) | 2005-03-24 | — | — | WO | disclosed |
| US-5981491-A | PEPTIDES; METALLOENZYMES; TUMOR NECROSIS FACTOR | DARWIN DISCOVERY LIMITED (GB) | 1999-11-09 | — | — | US | disclosed |
| EP-0824543-A1 | PEPTIDE COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION, AND THEIR THERAPEUTIC USE | Chiroscience Limited (GB) | 1998-02-25 | — | — | EP | disclosed |
| WO-1996035711-A1 | PEPTIDE COMPOUNDS WHICH INHIBIT METALLOPROTEINASE AND TNF LIBERATION, AND THEIR THERAPEUTIC USE | CHIROSCIENCE LIMITED (GB) | 1996-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191344-A1 | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases | DAPK1, DUSP4, MARK4 | TDP1 165/4885L3MBTL1 4365/4885CYP1A2 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.